Investors

PMB’s focus is on launching clinical trials for GBM and DIPG using its product, Immune12, a complex biologic compound derived from marine organisms. GBM and DIPG are orphan diseases with no cure. Current treatments may extend life by several months but are not curative. Upon diagnosis, patients face a grim reality with little to no hope for recovery. While existing standard-of-care treatments like radiation and chemotherapy may extend life by a few months, they fall significantly short of providing a cure. Moreover, the side effects associated with these treatments can be severe and debilitating, further compromising the quality of life for patients.